youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
AMLX:NASDAQ
Amylyx Pharmaceuticals Inc
$28.04
arrow_downward
-2.84%(-0.82) 1D
$28.04
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 2, 4:00:02 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMLX...
Open
$28.84
High
$29.50
Low
$27.61
Mkt. cap
3.52B
Avg. vol.
1.30M
Volume
0.00
52-wk high
$41.13
52-wk low
$10.83
EPS
-$1.43
Beta
-0.10
Shares outstanding
125.51M
No. of employees
136
Open
$28.84
High
$29.50
Low
$27.61
Mkt. cap
3.52B
Avg. vol.
1.30M
Volume
0.00
52-wk high
$41.13
52-wk low
$10.83
EPS
-$1.43
Beta
-0.10
Shares outstanding
125.51M
No. of employees
136
News stories
From web sources and news partners
Profile
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
About Amylyx Pharmaceuticals Inc